H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs GLOBAL PHARMATEK LLC

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
GLOBAL PHARMATEK LLC
NJRank #FEIN 27-4588592

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPGLOBAL PHARMATEK LLC
Total filings80,813350
Certified %98.23%92.29%
Denied %1.09%0.86%
Withdrawn %0.61%0.57%
Cert-withdrawn %0.07%6.29%
Rank#4
Active yearsFY2010–FY2026FY2012–FY2024
Worksite statePANJ

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — GLOBAL PHARMATEK LLC

DOL case-status mix.

Outcome breakdown: Certified 92.3%, Cert-withdrawn 6.3%, Withdrawn 0.6%, Denied 0.9%
Outcome breakdown
OutcomeShare
Certified92.3%
Cert-withdrawn6.3%
Withdrawn0.6%
Denied0.9%
Certified92.3%
Cert-withdrawn6.3%
Withdrawn0.6%
Denied0.9%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
GLOBAL PHARMATEK LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20100
FY20110
FY201212
FY201349
FY201489
FY2015130
FY20162
FY20177
FY20182
FY201933
FY202014
FY20213
FY20224
FY20231
FY20244
FY20250
FY20260

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — GLOBAL PHARMATEK LLC

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.